

Age matters: differences in exercise-induced cardiovascular remodeling in young and middle aged healthy sedentary individuals.

Torlasco C^{1,2*}, D'Silva A^{3*}, Bhuvana AN^{4,5}, Faini A¹, Augusto J^{4,5}, Knott KD^{4,5}, Benedetti G⁶, Jones S⁴, Van Zalen J⁴, Scully P^{4,5}, Lobascio F⁵, Parati G^{1,2}, Lloyd G⁴, Hughes AD^{4,7}, Manisty CH^{4,5}, Sharma S³, Moon JC^{4,5}

1. Department of Cardiovascular, Neural and Metabolic Sciences, S.Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy

2. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

3. Cardiovascular Sciences Research Centre, St. George's, University of London, London, United Kingdom

4. Institute of Cardiovascular Science, University College London, UK

5. Barts Heart Centre, London, UK

6. Guy's and St Thomas' NHS Foundation Trust

7. MRC Unit for Lifelong Health and Ageing at UCL, London, UK

*These authors contributed equally to the work

Word count:

4466 words (text + references) + 2 figures + 2 tables: 5466 (max 5000)

44 bibliography articles

Correspondence:

Prof. James C Moon

Barts Heart Centre, The Cardiovascular Magnetic Resonance Imaging Unit and The Inherited Cardiovascular Diseases Unit, St Bartholomew's Hospital, West Smithfield

London EC1A 7BE, United Kingdom

Tel: +442034563081 Fax: +442034563086

Email: j.moon@ucl.ac.uk

Abstract

Aims: Remodeling of the cardiovascular system (including heart and vasculature) is a dynamic process influenced by multiple physiological and pathological factors. We sought to understand whether remodeling in response to a stimulus, exercise training, altered with healthy ageing.

Methods: 237 untrained healthy male and female subjects volunteering for their first-time marathon were recruited. At baseline and after 6 months of unsupervised training, race completers underwent tests including 1.5T cardiac magnetic resonance, brachial and non-invasive central blood pressure (BP) assessment. For analysis, runners were divided by age into under or over 35 years (U35, O35).

Results: Injury and completion rates were similar among groups. 138 runners (U35: n=71, females=49%; O35: n=67, females=51%) completed the race. On average, U35 were faster by 37 minutes (12%). Training induced a small increase in left ventricle (LV) mass in both groups (3g/m^2 , $p<0.001$), but U35 also increased ventricular cavity sizes (LV end-diastolic volume [EDV]_i +3%; LV end-systolic volume [ESV]_i +8%; right ventricle [RV] EDV_i +4%, RVESV_i +5%; $p<0.01$ for all). Systemic aortic compliance fell in the whole sample by 7% ($p=0.020$) and, especially in O35, also systemic vascular resistance (-4% in the whole sample, $p=0.04$) and blood pressure (systolic/diastolic, whole sample: brachial -4/-3 mmHg, central -4/-2 mmHg, all $p<0.001$; O35: brachial -6/-3 mmHg, central -6/-4 mmHg, all $p<0.001$).

Conclusion: Medium-term, unsupervised physical training in healthy sedentary individuals induces measurable remodeling of both heart and vasculature. This amount is age dependent, with predominant cardiac remodeling when younger and predominant vascular when older.

Keywords:

1) Physical training; 2) Cardiac remodeling; 3) Vascular remodeling; 4) Healthy ageing;

Introduction

“Cardiac plasticity” is the ability of the myocardium to undergo reversible structural and functional changes via “remodeling”, a process that appears evolved to optimize performance.[1] It starts at the molecular level and leads to changes in myocytes, but also affects the extracellular compartments,[2]–[6] translating into changes in wall thickness, chambers volumes and ventricular function which can, in some cases, double the size of the heart.[1] Similar plasticity is found in the vascular tree where macroscopically measurable changes in large vessels occur, including intima-media thickness, media-to-lumen ratio and elastic properties.[7]

The overall cardiovascular phenotype at any given time is determined by age, sex, [8] environmental factors (for example sedentary vs athletic), disease and genetics.[9][10], [11] Our knowledge of their relative contributions is incomplete. Ageing-related cardiac changes include a reduction in myocyte numbers (30% fall from second to seventh decade)[3],[2] with hypertrophy of remaining cells in addition to alterations in contractile proteins and collagen, leading to a stiffer heart.[6], [12] Vascular changes include reduced capillary density, altered collagen and elastin, and an increase in vascular stiffness, with increased peripheral resistance.[7] The two compartments interact directly via vascular coupling (volume and pressure loading) and through paracrine and neurohumoral control.[13], [14]

These changes may be reversible and plastic, but current knowledge is incomplete. Physiological exercise can explore the system: intense physical exercise leads to the “athlete’s heart”, while moderate training has been associated with increased capillarity, enlargement of conduit vessels [15] and delayed age-related increase in cardiac stiffening.[16]

Society is currently changing with 1) demographic ageing, with 22% of people expected to be over 65 by 2040;[17] 2) activity changes, i.e. increasingly sedentary lifestyles for some and increasing recreational running in others;[18] 3) altering emergent disease profiles, e.g. heart failure with preserved ejection fraction (HFpEF).[19] Accordingly, we wished to explore the relationship between healthy ageing and differences in cardiovascular adaptation in response to a stimulus, here moderate, unsupervised, medium-term aerobic exercise.

Methods

This was a prospective observational study, evaluating first-time marathon runners of both sexes, unaware of pre-existing cardiovascular conditions and not on medications, sedentary. Exclusion criteria included cardiovascular disease uncovered during preliminary investigations and contraindication to cardiac magnetic resonance (CMR). The study was advertised by email over 2 consecutive years to novice marathon runners, identified through the database records of the Virgin Money London Marathon, and on social media. Interested runners contacted a dedicated call center and were given an appointment for eligibility assessment and recruitment.

The study protocol has already been described [20]–[23]. Briefly, it included:

- 1) cardiopulmonary exercise test (CPET) using a semi-recumbent tilting cycle ergometer (Schiller ERG 911 BP/LS, Schiller, Switzerland) and a dedicated metabolic cart (Quark CPET, COSMED, Rome, Italy).[24]
- 2) Allometry and bioimpedance (BC-418, Tanita, USA),
- 3) Cardiac magnetic resonance (CMR) (1.5T Aera, Siemens Medical Solution, Erlangen, Germany), performed accordingly to international guidelines,[25] including parametric T1 mapping and extracellular volume (ECV), pulse wave velocity (PWV) measured with phase-contrast MR imaging and late gadolinium enhancement (LGE) images.[26] Image analysis was performed by 3 experienced operators. See Table S2 for intra- and inter- operator reproducibility data.
- 4) Brachial and non-invasive central- blood pressure (BP) assessment and wave analysis using a Cardioscope II BP+ device (USCOM, Sydney, NSW, Australia).[27]
- 5) Hematocrit and serum creatinine.

Systemic vascular resistance (SVR) and systemic aortic compliance (SAC) were also calculated as follows:

$$SVR = \frac{MAP}{CO} * 80$$

$$SAC = \frac{SV}{SBP - DBP}$$

Where SVR: systemic vascular resistance; MAP: mean arterial pressure; CO: cardiac output; SAC: systemic arterial compliance, SBP: systolic BP; DBP: diastolic BP.

All measurements were carried out before training started, 6 months before the marathon, and repeated between 1 and 3 weeks after the race, to avoid the acute effects of the race. It was recommended that participants followed the race organisers' "Beginner's Training Plan" (see Appendix 1), but alternative training plans were allowed. The calculation of synthetic ECV [28] was preferred because haematocrit, needed in order to calculate normal ECV, was unavailable at follow-up in 35 subjects due to the cyberattack that affected NHS and the hospital laboratory immediately before the study dates.

All procedures were in accordance with the principles of the Helsinki declaration, all participants gave written informed consent, and the study was approved by the London-Queen Square National Research Ethics Service Committee(15/LO/0086).

Statistical analysis

Quantitative variables are expressed as mean±standard deviation (SD) or (range) and categorical variables as an absolute number with percentage in parentheses. Only the subjects who completed the study were included in the analysis. To assess the cardiovascular effects of aerobic exercises in different age group, we used linear mixed-effects models accounting for repeated measurements with an unstructured covariance matrix, fitting the models by maximizing the restricted log-likelihood followed by a posteriori contrasts when applicable. False Discovery Rate algorithm was used for multiple post-hoc comparisons. The variables were transformed to handle possible violations of the hypothesis of normality of the residuals. For analysis of the age effect, we split recruited runners into two groups, "under 35" (U35) and "over 35" (O35), when a runner is <35 or ≥35 years respectively, accordingly to the classification of "young" versus "master" athlete. Linear regression analysis was also performed (results in Appendix 2). An α level of 0.05 was used for all hypothesis tests; analyses were performed using R Core Team software (2018), Vienna, Austria.

Results

Study population

Two hundred and thirty-seven runners were recruited. Among them 166 (70%) completed the race, 52 (22%) interrupted their training following musculoskeletal injury, 19 (8%) did not compete for other reasons. Among the race completers, 27 did not attend for follow-up, 1 was excluded after being diagnosed with hypertension. The final cohort consisted of 138 subjects who underwent evaluations at 180 ± 10 days before the London Marathon and 16 ± 8 days after (Figure 1). Baseline mean age was 37 ± 10 years (range 21-69y.o.), 51% were females (mean age 37 ± 10 years, 47% <35 years), 49% were males (mean age 37 ± 11 years, 54% <35 years). Reported median hours of training per week were 1.9.

See Table 1 for full details.

Baseline characteristics

We did not find any significant difference in the baseline characteristics between the subjects who completed the study or dropped out. Race finishers were similar in age and gender (U35: $n=71$, mean age 29 ± 4 y, females=49%; O35: $n=67$, mean age 46 ± 7 y, females=51%). The prevalence of former smokers was lower in U35 than in O35 (10% vs 32% respectively, $p=0.002$). No differences were observed for ethnicity and blood tests results. See Table 1 and 2.

Marathon completion rate and injury rate during training did not differ between age groups (Figure 1). Mean race time (HH:MM) was 4:44 (range: 2:57-7:57) in the whole cohort. U35 were faster (mean race time in U35: 4:38 [range 2:56–6:51] against 5:15 [range 3:27–7:57] in O35).

All participants achieved an RER of 1.1 or greater at the baseline CPET. Age predicted peak oxygen uptake was $109 \pm 17\%$, without significant differences between groups, although absolute physical performance was superior in U35 than in O35 for peak oxygen uptake ($+5.6$ ml/kg/min, $p<0.001$), maximal reached power ($+13$ W, $p=0.012$) and exercise time ($+166$ seconds, $p<0.001$).

Mean height, weight, body surface area (BSA) did not differ between groups. On average, body mass index (BMI) was high-normal (24.4, range 16.7-35.2), and lower in U35 than O35 (U35: 23.6 ± 0.3 ; O35: 25.1 ± 0.4 , $p=0.009$).

Average biventricular chambers size and LV mass indexed for BSA were normal in the whole sample.[29] All volumes and mass were higher in U35 than in O35 (LV EDVi: +8ml/m²; LV ESVi: +5ml/m², RV EDVi and ESVi: +10ml/m²; LV mass +6gr/m²; p<0.001 for all). Native T1 values and synthetic ECV were within the normal range and not different between groups.[26] There was basal infero-lateral mid-myocardial non-ischemic LGE in one male subject in the O35, both before and after training (unchanged).

Average BP was normal in the whole sample, but lower in U35 than in O35 by 5/3mmHg for brachial SBP/DBP (p=0.02/0.03 respectively) and by 6/3mmHg for central SBP/DBP (p=0.004 for cSBP and p=0.03 for cDBP). Arterial PWV in the whole aorta was 6±15m/s, lower in U35 than O35 by 1.4m/sec (p <0.001).[20] Similarly, SVR were on average 1135dyn·s/cm⁵, significantly lower in U35 than in O35 by 173dyn·s/cm⁵ (p <0.001). Finally, SAC of the whole sample was 3.0 ±8 ml/m², higher in U35 than in O35 (+0.3 ml/m², p=0.001).

See Table 2 and Table S1.

Follow up

Cardiopulmonary exercise testing

After training, there were small increases in overall fitness. Mild improvement was observed in peak oxygen uptake (+1ml/kg/min, p=0.035). Exercise time increased on average by 21seconds (p=0.010) and peak power by 4W (p=0.002). Subgroup analysis showed these changes in the U35 only (exercise time: +6%, peak power: +5%, peak VO₂ +3%; p<0.01, p<0.01 and p<0.05 respectively). Resting heart rate was unchanged at follow-up.

Allometry

After training, weight fell by 900g (p=0.001) and body fat by 1% (p=0.006) driven by O35 (on average -2%, p<0.001). Height decreased by 6mm in both groups. See Table2.

Cardiac remodeling

After training, biventricular volumes increased by an average of 2ml/m² (EDVi) and 1ml/m² (ESVi) (p<0.05 for both). At post hoc analysis, the chambers size increase was observed only in the U35 (LVEDVi: +3%, LVESVi: +8%, RVEDVi: +4%, RVESVi: +5%, p<0.001 for all), while no change was observed in O35. A similar 4% (~3g/m²) increase in LV mass was observed in both groups (p<0.001) representing mild concentric remodeling (LV mass/volume ratio increase of 0.2), driven by O35, in whom LV mass/volume ratio went from 0.73±0.1 to 0.76±0.1 (p=0.001).

Synthetic ECV and native myocardial T1 mapping were unchanged after training. No changes were observed in the myocardial partition coefficient, post-contrast T1 myocardial, full blood count or kidney function in either group.

See Table 2 and Table 1S.

Systemic hemodynamics and vascular remodeling.

There was a mean 4% decrease in SVR after training (p=0.04), driven by O35 (baseline vs follow-up in U35: p=0.31; O35: p=0.060;), associated with a 7% reduction in SAC (p=0.020), similar in U35 and O35 (baseline vs follow-up p=0.002 for both), and a mild reduction in the PWV of the whole aorta (p=0.040), without differences between age groups. Training reduced BP, with the largest falls observed in O35. Brachial SBP/DBP dropped by 3/1mmHg in U35 (p=0.030 for SBP, p=0.08 for DBP) and by 6/3mmHg in O35 (p<0.001 for both SBP and DBP); central SBP/DBP dropped by 3/2mmHg in U35 (p=0.05 for SBP, p=0.004 for DBP) and dropped by 6/4mmHg in O35 (p<0.001 for both SBP and DBP).

See Table 2 and Table S1.

Discussion

This study explored the cardiac and vascular remodeling occurring in healthy sedentary adults of different age groups undergoing medium-term, unsupervised physical training of mild intensity. Our main findings were a more pronounced cardiac remodeling observed in younger subjects and more vascular changes, associated with early cardiac remodeling features, in older subjects (Figure 2). Specifically, the U35 showed an increase in ventricular LV size consistent with 6-months of endurance training in a similar age-group,[30] associated with an increase in LV mass consistent with a light training schedule and a very mild reduction in BP. On the other hand, in the O35s only early cardiac remodeling was noted (i.e. a LV mass increase similar to O35 but no measurable cavity dilatation), associated with a more marked reduction in BP and SVR, corresponding to the effect of a low-dose BP lowering drug on BP and to an overall reduction in vascular age of approximately four years. [20],[21], [31]

Ageing is associated with impaired cardiovascular elasticity [32],[7] and reduced cardiac responsivity to sympathetic stimulation.[33] Histologically, these features correspond to 1) quantitative and qualitative changes in collagen, 2) a reduction in cardiomyocyte number with compensatory hypertrophy of the remaining cells [1] and 3) changes in cardiac innervation.[6], [12] Functionally, this translates into cardiac diastolic dysfunction and dromotropic/inotropic impairment, associated with increased afterload and leading to increased ventricular filling pressure and impaired exercise tolerance. Combined, cardiac and vascular ageing is critical in determining exercise tolerance: in fact, the impairment in cardiac response during strenuous exercise observed in aged people [34] is entirely reversible by reducing the loading conditions. [35]

On the other hand, endurance training is known to increase stroke volume, improve endothelial function and coronary perfusion, decrease peripheral resistance, lower blood pressure and induce cardiac and skeletal muscle cell remodeling. [15], [32], [36]

Here, in the O35 group, we observed an improvement in vascular function, and peripheral resistance, consistent with previous observations. [37] We hypothesize that mild-intensity training may unload the myocardium and improve ventriculo-arterial coupling, thereby increasing cardiovascular efficiency meaning that stimulated cardiac growth was counteracted – an overall beneficial set of linked changes.[38]

For the U35s, possessing a greater number of smaller myocytes, an effective response to sympathetic stimulation and loading conditions already well coupled to vascular function, a mild increase in LV volumes along the lines expected for “athlete’s heart” was seen.[39], [40]

Finally, no changes in ECV were observed in different study conditions, arguably because any changes were proportionate with equal changes in intracellular and extracellular compartments or because the amount of exercise undertaken was insufficient to induce a measurable change in the cellular/extracellular tissue component ratio.[41]

We acknowledge a number of limitations, including the lack of a non-running control group, a potential selection bias related to the availability to take part in a research study and the lack of ethnic diversity. Here, the U35s and O35s were all first-time marathon runners, but they differ by more than just age. Although it is not possible to fully unravel the contribution of differences (birth cohort bias with different nutrition, gestational conditions and lifestyle, as suggested by ex-smoker rates different between cohorts; baseline fitness; training schedule; commitment; age-related whole-organism responsivity to training) and the net amount of physical exercise against age in determining cardiovascular remodeling, baseline age adjusted peak oxygen consumption and marathon completion and injury rates were not age dependent, suggesting that baseline fitness, training schedules and commitment were not the primary cause of the remodeling differences. Actual physical activity during the training period is unknown due to excessive number of missing data, but average completion times exceed those reported in age-matched wide cohorts (including professional athletes) by ~40 minutes in U35 and by ~70 minutes in O35,[18] suggesting that training intensity was mild. Exercise-induced cardiovascular remodeling is dose-dependent, with mass increase observed earlier than volume increase. [30] The mild amount of cardiovascular remodeling observed is proportional to the entity of training undertaken, and more marked changes would have been unexpected. We believe that the potential significance of our results is also related to their epidemiological impact: this kind and entity of exercise is generalizable to the real-world population and is feasible outside a structured training program.

Finally, the study had a high drop-out rate (42%), mostly due to musculoskeletal injury (71% of total drop-out). We did not find any differences between study completers and non-completers at baseline examination

(Table 3S), thus excluding a selection bias were study completers could be a selection of the cohort with better cardiovascular adaptation to exercise.

With the aforementioned limitations, this study may contribute to cardiac rehabilitation research, where vascular function and peripheral resistance changes could be tested as an efficacy endpoint. There may also be relevance to HFpEF, where a component of reversible vascular dysfunction may explain the benefits observed after physical training despite unchanged cardiac function – the idea that at least some HFpEF has a significant and reversible vascular dysfunction component is not widely considered.[42], [43] Additional points that need clarification are the mechanisms underlying these observations and the impact of sex on cardiovascular ageing and its interaction with physical exercise. [37], [44]

In conclusion, these data show how different age groups shift on the training-induced cardiovascular remodeling spectrum, with more relevant cardiac changes observed in the youth, resembling an early athlete's heart phenotype, and more vascular changes, tending to improved efficiency through optimization of cardiac load and corresponding to a decrease in vascular age, in the elderly.

Acknowledgements

We thank the study participants for voluntarily giving their time. We are grateful to Virgin London Marathon, especially Hugh Brasher and Penny Dain, for their support in the advertisement of the study and recruitment of participants, and to COSMED (Rome, Italy) for providing cardiopulmonary exercise testing equipment and technical support free of charge. We are grateful to the entire marathon study team performing investigations. In addition to the authors of this manuscript, The Marathon Study group included the following staff: Amna Abdel-Gadir, Thomas Treibel, Stefania Rosmini, Manish Ramlal, Gabriella Captur, Katia D Menacho Medina, Yang Ye, Niromila Nadarajan, Nabila Mughal, Sunita Chauhan, Shino Kiriakose, Tolu Akinola, Cheelo Simaanya, Lizette Cash, Cavan McGurck, Patricia Feutcher, James Willis, David Hoare, James Malcolmson, Pamela de la Cruz, Annabelle Freeman, Delfin Encarnacion, Lesley Hart, Jack Kaufman, Frances Price, Rueben Dane, Karen Armado, Gemma Cruz, Lorna Carby, Tiago Fonseca, Fatima Niones, Zeph Fanton, Jim Pate, Joe Carlton, Sarah Anderson, Rob Hall, Sam Liu, Sonia Bains, Claire Kirkby, Pushpinder Kalra, Raghuveer Singh, Bode Ensam, Tee J Yeo, Rachel Bastiaenen, Della Cole, Jacky Ah- Fong, Sue Brown, Sarah Horan, Ailsa McClean, Kyle Conley, Luke Horsfield, Mark McLaren, Elizabeth Clough, Daniel Key, Riyaz Patel and Sanjeev Bhattacharyya. From our funders Cardiac Risk in the Young we are particularly grateful to Steve Cox and Azra Loncarevic-Srmic for their additional support with administration and transport.

Funding

The study was funded by the British Heart Foundation (FS/15/27/31465), Cardiac Risk in the Young, and the Barts Cardiovascular Biomedical Research Centre. AD was funded by a clinical research training fellowship from the British Heart Foundation, UK (FS/15/27/31465). AB was supported by a doctoral research fellowship from the British Heart Foundation (FS/16/46/32187). AH received support from the British Heart Foundation (PG/13/6/29934), the National Institute for Health Research University College London Hospitals Biomedical Research Centre and works in a unit that receives support from the UK Medical Research Council (Programme Code MC_UU_12019/1). JCM and CM are directly and indirectly supported by the University College London Hospitals, and Barts Hospital NIHR Biomedical Research Centres.

Conflict of interest:

The authors report no relationships that could be construed as a conflict of interest.

Authors' contribution:

AD, ANB, ADH, GL, CHM, SS, JCM contributed to the conception or design of the work. CT, AD, JAA, ANB, KDK, AF, GB, SJ, JVZ, PS, IL contributed to the acquisition, analysis, or interpretation of data. CT

drafted the manuscript. AD, ANB, GP, ADH, GL, CHM, SS, JCM critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

References

- [1] J. A. Hill and E. N. Olson, "Cardiac Plasticity," *New England Journal of Medicine*, vol. 358, no. 13, pp. 1370–1380, Mar. 2008, doi: 10.1056/NEJMr072139.
- [2] P. Anversa, B. Hiler, R. Ricci, G. Guideri, and G. Olivetti, "Myocyte cell loss and myocyte hypertrophy in the aging rat heart," *J. Am. Coll. Cardiol.*, vol. 8, no. 6, pp. 1441–1448, Dec. 1986.
- [3] G. Olivetti, M. Melissari, J. M. Capasso, and P. Anversa, "Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy.," *Circulation Research*, vol. 68, no. 6, pp. 1560–1568, Jun. 1991, doi: 10.1161/01.RES.68.6.1560.
- [4] K. Konstantinidis, R. S. Whelan, and R. N. Kitsis, "Mechanisms of Cell Death in Heart Disease," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, no. 7, pp. 1552–1562, Jul. 2012, doi: 10.1161/ATVBAHA.111.224915.
- [5] A. Biernacka and N. G. Frangogiannis, "Aging and Cardiac Fibrosis," *Aging Dis*, vol. 2, no. 2, pp. 158–173, Apr. 2011.
- [6] M. A. Horn and A. W. Trafford, "Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodeling," *Journal of Molecular and Cellular Cardiology*, vol. 93, pp. 175–185, Apr. 2016, doi: 10.1016/j.yjmcc.2015.11.005.
- [7] N. F. Renna, N. de las Heras, and R. M. Miatello, "Pathophysiology of Vascular Remodeling in Hypertension," *International Journal of Hypertension*, vol. 2013, pp. 1–7, 2013, doi: 10.1155/2013/808353.
- [8] B. A. Parker, M. J. Kalasky, and D. N. Proctor, "Evidence for sex differences in cardiovascular aging and adaptive responses to physical activity," *European Journal of Applied Physiology*, vol. 110, no. 2, pp. 235–246, Sep. 2010, doi: 10.1007/s00421-010-1506-7.
- [9] E. B. Schelbert *et al.*, "Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome," *JAMA Cardiology*, vol. 2, no. 9, p. 995, Sep. 2017, doi: 10.1001/jamacardio.2017.2511.
- [10] J. I. van Waning *et al.*, "Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy," *Journal of the American College of Cardiology*, vol. 73, no. 13, pp. 1601–1611, Apr. 2019, doi: 10.1016/j.jacc.2018.12.085.
- [11] B. J. van Varik, R. J. M. W. Rennenberg, C. P. Reutelingsperger, A. A. Kroon, P. W. de Leeuw, and L. J. Schurgers, "Mechanisms of arterial remodeling: lessons from genetic diseases," *Frontiers in Genetics*, vol. 3, 2012, doi: 10.3389/fgene.2012.00290.
- [12] C. R. Gazoti Debessa, L. B. Mesiano Maifrino, and R. Rodrigues de Souza, "Age related changes of the collagen network of the human heart," *Mech. Ageing Dev.*, vol. 122, no. 10, pp. 1049–1058, Jul. 2001.
- [13] A. Pasipoularides, "Diastolic filling vortex forces and cardiac adaptations: probing the epigenetic nexus," *Hellenic J Cardiol*, vol. 53, no. 6, pp. 458–469, Dec. 2012.
- [14] H. D. Intengan and E. L. Schiffrin, "Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis," *Hypertension*, vol. 38, no. 3 Pt 2, pp. 581–587, Sep. 2001.
- [15] B. M. Prior, P. G. Lloyd, H. T. Yang, and R. L. Terjung, "Exercise-induced vascular remodeling," *Exerc Sport Sci Rev*, vol. 31, no. 1, pp. 26–33, Jan. 2003.
- [16] M. J. Schindler, V. Adams, and M. Halle, "Exercise in Heart Failure—What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?," *Current Heart Failure Reports*, Jun. 2019, doi: 10.1007/s11897-019-00428-z.
- [17] B. J. North and D. A. Sinclair, "The Intersection Between Aging and Cardiovascular Disease," *Circulation Research*, vol. 110, no. 8, pp. 1097–1108, Apr. 2012, doi: 10.1161/CIRCRESAHA.111.246876.
- [18] P. T. Nikolaidis, I. Cuk, V. J. Clemente-Suárez, E. Villiger, and B. Knechtle, "Number of finishers and performance of age group women and men in long-distance running: comparison among 10km, half-

- marathon and marathon races in Oslo," *Research in Sports Medicine*, pp. 1–11, Feb. 2020, doi: 10.1080/15438627.2020.1726745.
- [19] F. Duca *et al.*, "Gender-related differences in heart failure with preserved ejection fraction," *Scientific Reports*, vol. 8, no. 1, Dec. 2018, doi: 10.1038/s41598-018-19507-7.
- [20] A. N. Bhuva *et al.*, "Non-invasive assessment of ventriculo-arterial coupling using aortic wave intensity analysis combining central blood pressure and phase-contrast cardiovascular magnetic resonance," *European Heart Journal - Cardiovascular Imaging*, Sep. 2019, doi: 10.1093/ehjci/jez227.
- [21] A. N. Bhuva *et al.*, "Training for a first-time marathon reverses age-related aortic stiffening: a prospective longitudinal cohort study.," *JACC*, vol. in press, 2020.
- [22] S. Jones *et al.*, "Improved Exercise-Related Skeletal Muscle Oxygen Consumption Following Uptake of Endurance Training Measured Using Near-Infrared Spectroscopy," *Frontiers in Physiology*, vol. 8, Dec. 2017, doi: 10.3389/fphys.2017.01018.
- [23] A. D'Silva *et al.*, "Cardiovascular Remodeling Experienced by Real-World, Unsupervised, Young Novice Marathon Runners," *Frontiers in Physiology*, vol. 11, Mar. 2020, doi: 10.3389/fphys.2020.00232.
- [24] S. Sharma *et al.*, "Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes," *J. Am. Coll. Cardiol.*, vol. 36, no. 3, pp. 864–870, Sep. 2000, doi: 10.1016/s0735-1097(00)00816-0.
- [25] C. M. Kramer *et al.*, "Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update," *Journal of Cardiovascular Magnetic Resonance*, vol. 15, no. 1, p. 91, 2013, doi: 10.1186/1532-429X-15-91.
- [26] D. R. Messroghli *et al.*, "Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)," *Journal of Cardiovascular Magnetic Resonance*, vol. 19, no. 1, Dec. 2017, doi: 10.1186/s12968-017-0389-8.
- [27] B. Williams *et al.*, "2018 ESC/ESH Guidelines for the management of arterial hypertension," *European Heart Journal*, vol. 39, no. 33, pp. 3021–3104, Sep. 2018, doi: 10.1093/eurheartj/ehy339.
- [28] T. A. Treibel *et al.*, "Automatic Measurement of the Myocardial Interstitium," *JACC: Cardiovascular Imaging*, vol. 9, no. 1, pp. 54–63, Jan. 2016, doi: 10.1016/j.jcmg.2015.11.008.
- [29] L. Hudsmith†, S. Petersen†, J. Francis, M. Robson, and S. Neubauer, "Normal Human Left and Right Ventricular and Left Atrial Dimensions Using Steady State Free Precession Magnetic Resonance Imaging," *Journal of Cardiovascular Magnetic Resonance*, vol. 7, no. 5, pp. 775–782, Oct. 2005, doi: 10.1080/10976640500295516.
- [30] A. Arbab-Zadeh *et al.*, "Cardiac Remodeling in Response to 1 Year of Intensive Endurance Training," *Circulation*, vol. 130, no. 24, pp. 2152–2161, Dec. 2014, doi: 10.1161/CIRCULATIONAHA.114.010775.
- [31] S. Julius *et al.*, "Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker," *New England Journal of Medicine*, vol. 354, no. 16, pp. 1685–1697, Apr. 2006, doi: 10.1056/NEJMoa060838.
- [32] A. Arbab-Zadeh *et al.*, "Effect of Aging and Physical Activity on Left Ventricular Compliance," *Circulation*, vol. 110, no. 13, pp. 1799–1805, Sep. 2004, doi: 10.1161/01.CIR.0000142863.71285.74.
- [33] E. G. Lakatta, "Cardiovascular regulatory mechanisms in advanced age.," *Physiological Reviews*, vol. 73, no. 2, pp. 413–467, Apr. 1993, doi: 10.1152/physrev.1993.73.2.413.
- [34] J. L. Fleg *et al.*, "Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women," *Journal of Applied Physiology*, vol. 78, no. 3, pp. 890–900, Mar. 1995, doi: 10.1152/jappl.1995.78.3.890.
- [35] A. Nussbacher *et al.*, "Hemodynamic effects of unloading the old heart," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 277, no. 5, pp. H1863–H1871, Nov. 1999, doi: 10.1152/ajpheart.1999.277.5.H1863.
- [36] S. Gielen, G. Schuler, and R. Hambrecht, "Exercise Training in Coronary Artery Disease and Coronary Vasomotion," *Circulation*, vol. 103, no. 1, Jan. 2001, doi: 10.1161/01.CIR.103.1.e1.

- [37] J. Eigendorf *et al.*, "Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women," *European Journal of Preventive Cardiology*, vol. 26, no. 17, pp. 1903–1906, Nov. 2019, doi: 10.1177/2047487319849505.
- [38] B. H. Lorell and B. A. Carabello, "Left ventricular hypertrophy: pathogenesis, detection, and prognosis," *Circulation*, vol. 102, no. 4, pp. 470–479, Jul. 2000.
- [39] F. D'Ascenzi *et al.*, "Cardiac Magnetic Resonance Normal Reference Values of Biventricular Size and Function in Male Athlete's Heart," *JACC: Cardiovascular Imaging*, Dec. 2018, doi: 10.1016/j.jcmg.2018.09.021.
- [40] A. W. Bjerring *et al.*, "The developing athlete's heart: a cohort study in young athletes transitioning through adolescence," *European Journal of Preventive Cardiology*, vol. 26, no. 18, pp. 2001–2008, Dec. 2019, doi: 10.1177/2047487319862061.
- [41] A. K. McDiarmid *et al.*, "Athletic Cardiac Adaptation in Males Is a Consequence of Elevated Myocyte Mass," *Circulation: Cardiovascular Imaging*, vol. 9, no. 4, Apr. 2016, doi: 10.1161/CIRCIMAGING.115.003579.
- [42] S. Maréchaux *et al.*, "Vascular and Microvascular Endothelial Function in Heart Failure With Preserved Ejection Fraction," *Journal of Cardiac Failure*, vol. 22, no. 1, pp. 3–11, Jan. 2016, doi: 10.1016/j.cardfail.2015.09.003.
- [43] S. M. Hegde *et al.*, "Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)," *Circulation*, vol. 136, no. 11, pp. 982–992, Sep. 2017, doi: 10.1161/CIRCULATIONAHA.117.028002.
- [44] I. Csecs *et al.*, "The impact of sex, age and training on biventricular cardiac adaptation in healthy adult and adolescent athletes: Cardiac magnetic resonance imaging study," *European Journal of Preventive Cardiology*, vol. 27, no. 5, pp. 540–549, Mar. 2020, doi: 10.1177/2047487319866019.

Figure Legends:

Figure 1: Consort flow diagram illustrating subject recruitment and follow up. LQTS, long QT syndrome. U35: Under 35, <35 years old. O35: Over 35, \geq 35 years old.

Figure 2: Effects of ageing and physical training on the continuum of cardiovascular system remodeling. Panel 1: cardiac and vascular assessment by cardiac magnetic resonance (A: extracellular volume. B: function and mass; C, D, E: vascular function acquisitions to derive pulse wave velocity and arterial compliance by obtaining distance and high temporal resolution [G] flow and using least squares estimate of systolic upslopes [F]. Graphical schematics of systemic vascular resistance [H]). Panel 2: healthy ageing is characterized by a reduction in myocytes number, compensatory hypertrophy, and collagen alterations with vascular changes of arterial stiffening, increased pulse wave velocity, reduced arterial compliance and increased systemic vascular resistance. Physical training here induced cardiac plasticity (increase in left ventricular mass and chambers volume) in individuals <35years (U35), with minimal blood pressure changes (panel 1 to 3). In individuals aged \geq 35 years (O35), more vascular plasticity (systemic vascular resistance drop, systemic blood pressure drops) along with mild left ventricular mass increase (panel 2 to 4) are observed.

Figure 1





Figure 2



		Whole cohort (n=138)	U35 (≤34 years) (n=71)	O35 (≥35 years) (n=68)	p conditio n	p age	p interactio n	
BSA (m ²)	Baseline	1.9 ± 0.2	1.9 ± 0.2	1.9 ± 0.2	n.s.	n.s.	n.s.	
	Follow-up	1.9 ± 0.2	1.9 ± 0.2	1.9 ± 0.2				
CMR								
LV EDV (ml)	Baseline	162 ± 3.5	169 ± 3.8	154 ± 3.2	§	0.159	0.001	0.008
	Follow-up	164 ± 3.6	174 ± 3.9	152 ± 3.1	** §			
LV ESV (ml)	Baseline	57 ± 1.7	61 ± 1.8	52 ± 1.5		0.068	0.001	0.009
	Follow-up	58 ± 1.6	65 ± 1.8	52 ± 1.4	** §			
LV SV (ml)	Baseline	105 ± 2.4	108 ± 2.5	101 ± 2.1		0.83	0.047	0.341
	Follow-up	105 ± 2.3	110 ± 2.5	101 ± 2.0	§			
RV EDV (ml)	Baseline	164 ± 4.1	173 ± 4.2	155 ± 3.9		0.017	0.001	0.316
	Follow-up	168 ± 4.0	179 ± 4.2	157 ± 3.3	* §			
RV ESV (ml)	Baseline	65 ± 1.8	74 ± 2.0	55 ± 1.7				
	Follow-up	67 ± 2.0	77 ± 2.2	57 ± 1.8				
RV SV (ml)	Baseline	99 ± 2.1	99 ± 2.3	100 ± 2.0				
	Follow-up	101 ± 2.2	101 ± 2.4	100 ± 2.1				
LV mass (g)	Baseline	117 ± 3.2	121 ± 3.2	112 ± 3.1		<.0001	0.061	0.471
	Follow-up	121 ± 3.2	127 ± 3.2	116 ± 3.2	** * §			
Septal wall thickness (mm)	Baseline	6.8 ± 1.6	6.8 ± 1.7	6.8 ± 1.8		0.61	0.688	0.975
	Follow-up	6.9 ± 1.7	6.9 ± 1.7	6.9 ± 1.6				
Lateral wall thickness (mm)	Baseline	6.4 ± 2.2	6.7 ± 2.2	6.2 ± 1.8		0.678	0.258	0.514
	Follow-up	6.3 ± 1.6	6.4 ± 1.8	6.2 ± 1.6				
Native blood T1 (msec)	Baseline	1606 ± 9.8	160 ± 1.7	161 ± 1.2		0.176	0.543	0.212
	Follow-up	1600 ± 8.8	160 ± 2.8	159 ± 8.8				
Myocardial T1 post-Gd (msec)	Baseline	620 ± 4.6	632 ± 3.7	607 ± 5.1		0.8334	<.0001	0.47
	Follow-up	621 ± 4.1	635 ± 3.5	606 ± 4.2				
Blood T1 post-Gd (msec)	Baseline	503 ± 6.1	514 ± 5.1	491 ± 6.8		0.431	0.001	0.291
	Follow-up	508 ± 5.8	514 ± 4.9	490 ± 6.2				

Partition coefficient (Lambda)	Baseline	46 ± 3	45 ± 3		46 ± 4	§	0.444	0.045	0.45
	Follow-up	46 ± 3	45 ± 3		46 ± 4				
ECV	Baseline	27.1 ± 2.5	26.9 ± 2.3		27.4 ± 2.6		0.006	0.002	0.1
	Follow-up	26.2 ± 2.5	25.5 ± 5.7	**	27.3 ± 2.1				
LA volume (ml)	Baseline	69 ± 2.0	67 ± 2.2		70 ± 1.8		0.788	0.615	0.026
	Follow-up	69 ± 2.0	70 ± 2.1		68 ± 1.8				

CPET

% of predicted VO2 max (%)	Baseline	108 ± 1.7	106 ± 1.6		113 ± 1.8		0.204	0.146	0.371
	Follow-up	112 ± 1.9	110 ± 1.7		116 ± 2.1				
Peak HR (beats/min)	Baseline	164 ± 1.5	168 ± 1.4		159 ± 1.6	§	0.354	<.0001	0.072
	Follow-up	165 ± 1.5	172 ± 1.5		158 ± 1.5	§			
VE max	Baseline	95 ± 2.9	97 ± 3.0		92 ± 2.8		0.001	0.21	0.922
	Follow-up	88 ± 2.5	91 ± 2.6	*	85 ± 2.4	*			
Peak O2 pulse	Baseline	15.4 ± 4	16 ± 4		14.8 ± 4		0.167	0.019	0.629
	Follow-up	15.5 ± 4	16.4 ± 4		14.8 ± 4	§			

Biochemistry

Hb (g/dl)	Baseline	14 ± 1.3	14 ± 1.2		14 ± 1.4		0.004	0.88	0.148
	Follow-up	14 ± 1.3	14 ± 1.2		14 ± 1.6				
Hct (%)	Baseline	42 ± 4	42 ± 3		42 ± 4		0.002	0.174	0.003
	Follow-up	43 ± 4	43 ± 3	**	42 ± 4	*			
Creatinine (mg/dl)	Baseline	0.74 ± 1.3	0.74 ± 1.3		0.75 ± 1.2		0.002	0.166	0.386
	Follow-up	0.7 ± 1.5	70 ± 1.3		72 ± 1.7				

Table 1S: Baseline and post-marathon tests results for the patients who completed the study, whole sample, U35 and O35. Data are expressed as mean ±SD.

* = p pre vs post <0.05; ** = p pre vs post <0.01; *** = p pre vs post <.0001; § = p U35 vs O35 <0.05; §§ = p U35 vs O35 <0.01; §§§ = p U35 vs O35 <.0001.

BSA: body surface area. LV: left ventricle. EDV: end diastolic volume. ESV: end systolic volume. SV: stroke volume. EF: ejection fraction. CO: cardiac output. RV: right ventricle. LA: left atrium. ECV: extra cellular volume; HR: heart rate; VE: ventilatory equivalents; Hb: hemoglobin; Hct: hematocrit.

		Whole cohort (n= 138)	U35 (≤34 years) (n= 71)	O35 (≥35 years) (n= 67)	p condition	p age	p interaction
Allometry							
	Timepoint						
Height (cm)	Baseline	172.9 ± 9.5	174.3 ± 9.5	171.6 ± 9.4	0.001	0.09	0.8
	Follow-up	172.4 ± 9.5	173.7 ± 9.5 *	171.0 ± 9.5 **			
Weight (kg)	Baseline	73.2 ± 13	71.8 ± 12	74.5 ± 15	0.001	0.1	0.04
	Follow-up	72.3 ± 12	71.4 ± 10	73.1 ± 14 **			
BMI (Kg/m ²)	Baseline	24.4 ± 0.3	23.6 ± 0.3	25.1 ± 0.4 §§	0.1	0.009	0.08
	Follow-up	24.2 ± 0.3	23.6 ± 0.3	24.8 ± 0.4 §			
Body Fat (%)	Baseline	25 ± 8	23 ± 8	27 ± 8	0.006	0.021	0.06
	Follow-up	24 ± 9	23 ± 9	26 ± 9			
Blood Pressure							
Heart Rate (bpm)	Baseline	70 ± 13	71 ± 13	69 ± 13	0.3	0.9	0.4
	Follow-up	68 ± 12	68 ± 12	68 ± 13			
Brachial SBP (mmHg)	Baseline	121 ± 14	119 ± 11	124 ± 15 §§	<.001	0.026	0.049
	Follow-up	117 ± 13	116 ± 10 *	118 ± 15 *			
Brachial DBP (mmHg)	Baseline	75 ± 7	73 ± 5	76 ± 8 §§	<.001	0.020	0.028
	Follow-up	72 ± 7	72 ± 5	73 ± 8 *			
Central SBP (mmHg)	Baseline	112 ± 13	109 ± 11	115 ± 14 §§	<.001	0.004	0.043
	Follow-up	108 ± 13	106 ± 10	109 ± 15 *			
Central DBP (mmHg)	Baseline	76 ± 7	75 ± 5	78 ± 8 §§	<.001	0.030	0.011
	Follow-up	74 ± 7	73 ± 5 *	74 ± 8 *			
Central MAP (mmHg)	Baseline	87 ± 8	86 ± 7	91 ± 10 §§	<.001	0.009	0.016
	Follow-up	85 ± 10	84 ± 7 *	86 ± 10 *			
Pulse Wave Analysis							
PWV Arch (m/s)	Baseline	4.7 ± 1.4	3.9 ± 0.6	5.6 ± 1.6 §§	0.2	<.001	0.4
	Follow-up	4.6 ± 1.2	3.9 ± 0.6	5.3 ± 1.3 §			
PWV Descending aorta (m/s)	Baseline	8.3 ± 2.5	8.2 ± 2.6	8.5 ± 2.3	0.1	0.060	0.9
	Follow-up	7.9 ± 2.4	7.6 ± 4.9	8.2 ± 2.5			
PWV Whole aorta (m/s)	Baseline	6.0 ± 1.5	5.3 ± 1	6.7 ± 1.7 §§	0.038	<.001	0.8
	Follow-up	5.7 ± 1.4	5.1 ± 0.7	6.5 ± 1.7 §			
SAC (ml/m ²)	Baseline	3.0 ± 0.8	3.2 ± 0.7	2.9 ± 0.9 §§	0.022	0.001	>0.9
	Follow-up	3.2 ± 0.7	3.4 ± 0.7	3 ± 0.7 §§			
SVR (dyn·s/cm ⁵)	Baseline	1135 ± 262	1052 ± 239	1225 ± 275	0.034	0.001	0.5
	Follow-up	1092 ± 246	1029 ± 255	1160 ± 239			
CMR							
LV EDV i (ml/m ²)	Baseline	86 ± 14	90 ± 14	82 ± 13 §§	0.014	<.001	0.027
	Follow-up	88 ± 14	93 ± 15 **	82 ± 13 §			
LV ESV i (ml/m ²)	Baseline	30 ± 7	33 ± 8	28 ± 6 §§	0.019	<.001	0.023
	Follow-up	31 ± 8	35 ± 8 **	28 ± 7 §			
SV i (ml/m ²)	Baseline	56 ± 10	58 ± 10	54 ± 9 §	0.4	0.008	0.5
	Follow-up	57 ± 9	59 ± 10	54 ± 8			

LV EF (%)	Baseline	0.65 ± 0.05	0.64 ± 0.05	0.66 ± 0.05	§	0.4	0.001	0.254
	Follow-up	0.64 ± 0.05	0.63 ± 0.05	0.66 ± 0.05				
CO (l/min)	Baseline	6.7 ± 1.6	7.1 ± 1.7	6.3 ± 1.5	§	0.2	0.003	0.8
	Follow-up	6.6 ± 1.7	7 ± 1.8	6.1 ± 1.5				
LV mass i (g/m ²)	Baseline	62 ± 12	65 ± 12	59 ± 12	**	<.001	<.001	0.8
	Follow-up	65 ± 13	68 ± 12	62 ± 13	*			
LV mass/volume ratio	Baseline	0.72 ± 0.1	0.71 ± 0.1	0.73 ± 0.1		0.001	0.049	0.06
	Follow-up	0.74 ± 0.1	0.73 ± 0.1	0.76 ± 0.1	**			
RV EDV i (ml/m ²)	Baseline	88 ± 15	92 ± 15	82 ± 13		0.001	<.001	0.6
	Follow-up	90 ± 16	96 ± 17	85 ± 14	**			
RV ESV i (ml/m ²)	Baseline	35 ± 10	39 ± 9	29 ± 8		0.001	<.001	0.7
	Follow-up	36 ± 11	41 ± 10	31 ± 9	**			
RV SV i (ml/m ²)	Baseline	53 ± 9	53 ± 10	53 ± 9		0.08	0.9	0.6
	Follow-up	54 ± 9	55 ± 9	54 ± 8				
RV EF (%)	Baseline	0.61 ± 0.06	0.58 ± 0.05	0.65 ± 0.07	§§	0.4	<.001	0.7
	Follow-up	0.61 ± 0.05	0.57 ± 0.05	0.64 ± 0.07	§			
LA volume i (ml/m ²)	Baseline	51 ± 29	51 ± 28	50 ± 31		0.9	0.8	0.09
	Follow-up	50 ± 9	48 ± 26	52 ± 31				
Native myocardial T1 (msec)	Baseline	1009 ± 29	1009 ± 28	1009 ± 28		0.3	0.4	0.8
	Follow-up	1006 ± 33	1006 ± 33	1006 ± 33				
Synthetic ECV (%)	Baseline	26.3 ± 3	25.8 ± 3	26.7 ± 3		0.8	0.1	0.2
	Follow-up	26.3 ± 3	26 ± 3	26.6 ± 3				
CPET								
Exercise time (secs)	Baseline	674 ± 133	594 ± 104	760 ± 104		0.01	<.001	0.037
	Follow-up	695 ± 127	630 ± 115	764 ± 100	**			
Peak VO ₂ (ml/kg/min)	Baseline	34.5 ± 7.5	37.1 ± 6.8	31.4 ± 7		0.035	<.001	0.3
	Follow-up	35.6 ± 8.3	38.5 ± 8	31.9 ± 7	*			
Peak power (W)	Baseline	216 ± 57	222 ± 54	209 ± 59		0.002	0.012	0.001
	Follow-up	220 ± 60	232 ± 59	208 ± 60	**			
% of VO ₂ max	Baseline	109 ± 17	106 ± 16	113 ± 18		0.2	0.1	0.4
	Follow-up	113 ± 19	110 ± 17	116 ± 21				
Peak HR (bpm)	Baseline	163 ± 15	168 ± 14	159 ± 16		0.8	<.001	0.07
	Follow-up	165 ± 15	173 ± 15	158 ± 14				
RQ	Baseline	1.22 ± 0.09	1.20 ± 0.09	1.24 ± 0.08	*	0.02	0.01	0.51
	Follow-up	1.21 ± 0.08	1.19 ± 0.1	1.21 ± 0.07				

Table 2: Baseline and post-marathon tests results for the patients who completed the study, whole sample, U35 and O35. Data are expressed as mean ±SD.

* = p pre vs post <0.05; ** = p pre vs post <0.01; *** = p pre vs post <0.001; § = p U35 vs O35 <0.05; §§ = p U35 vs O35 <0.01; §§§ = p U35 vs O35 <0.001.

BMI: body mass index. SBP: systolic blood pressure. DBP: diastolic blood pressure. MAP: mean arterial pressure. PWV: pulse wave velocity. SAC: systemic arterial compliance. SVR: systemic vascular resistances. LV: left ventricle. EDV: end diastolic volume. ESV: end systolic volume. SV: stroke volume. EF: ejection fraction. CO: cardiac output. RV: right ventricle. LA: left atrium. ECV: extra cellular volume.